Ana
Fernández Montes
![Foto de Ana](/img/nophoto.png)
![Foto de Hospital General Universitario de Valencia](/img/noimage_org.png)
Hospital General Universitario de Valencia
Valencia, EspañaPublicacións en colaboración con investigadores/as de Hospital General Universitario de Valencia (9)
2024
-
Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?
British Journal of Cancer, Vol. 130, Núm. 5, pp. 777-787
-
Efficacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON-SEOM registry
Gastric Cancer, Vol. 27, Núm. 1, pp. 131-145
-
Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON–SEOM registry
Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1674-1686
-
Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain
Clinical and Translational Oncology, Vol. 26, Núm. 4, pp. 864-871
2023
-
Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry
Journal of Cancer Research and Clinical Oncology, Vol. 149, Núm. 7, pp. 4077-4089
-
The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy
Therapeutic Advances in Medical Oncology, Vol. 15
-
The Role of Financial Difficulties as a Mediator between Physical Symptoms and Depression in Advanced Cancer Patients
Current Oncology, Vol. 30, Núm. 6, pp. 5719-5726
-
Toxicities and Quality of Life during Cancer Treatment in Advanced Solid Tumors
Current Oncology, Vol. 30, Núm. 10, pp. 9205-9216